Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Change in Accured Expenses (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Change in Accured Expenses for 7 consecutive years, with $371000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Change in Accured Expenses rose 289.29% to $371000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was -$387000.0, a 82.22% increase, with the full-year FY2024 number at -$387000.0, up 82.22% from a year prior.
  • Change in Accured Expenses was $371000.0 for Q4 2024 at Actinium Pharmaceuticals, up from -$2.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.3 million in Q4 2022 to a low of -$2.8 million in Q1 2023.
  • A 4-year average of $201625.0 and a median of $75500.0 in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: surged 505.76% in 2022, then crashed 306.15% in 2024.
  • Actinium Pharmaceuticals' Change in Accured Expenses stood at $1.8 million in 2021, then grew by 28.39% to $2.3 million in 2022, then plummeted by 108.67% to -$196000.0 in 2023, then surged by 289.29% to $371000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Change in Accured Expenses are $371000.0 (Q4 2024), -$2.0 million (Q3 2024), and $1.7 million (Q2 2024).